Hypertension in the Cardio-Oncology Clinic.
Heart Fail Clin
; 15(4): 487-495, 2019 Oct.
Article
em En
| MEDLINE
| ID: mdl-31472884
ABSTRACT
As cancer therapies improve, the population of survivors of cancer has increased, and the long-term effects of cancer treatments have become more apparent. Cardiotoxicity is a well-established adverse effect of many antineoplastic agents. Hypertension is common in survivors of cancer, can be caused or worsened by certain agents, and has been shown to increase the risk of other cardiovascular diseases including heart failure. Pretreatment risk assessment and careful monitoring of blood pressure during therapy is essential. Aggressive management of preexisting or incident hypertension in survivors of cancer is paramount to decrease the risk of heart failure and other cardiovascular diseases in these patients.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Risco Ajustado
/
Cardiotoxicidade
/
Insuficiência Cardíaca
/
Hipertensão
/
Neoplasias
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Heart Fail Clin
Ano de publicação:
2019
Tipo de documento:
Article